Predicting toxicity in advanced lung cancer patients treated with platinum-based chemotherapy

2013 ◽  
Vol 2 (4) ◽  
pp. 281-293
Author(s):  
Georgios Ioannidis ◽  
John Souglakos ◽  
Vassilis Georgoulias
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Platinum Based Chemotherapy

Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis

2021 ◽  
Author(s):  
Lecai Xiong ◽  
Yi Cai ◽  
Xiao Zhou ◽  
Peng Dai ◽  
Yanhong Wei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Meta Analysis ◽  
Survival Rates ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Platinum Based Chemotherapy

Aim: To compare the survival of advanced lung cancer patients treated with immune checkpoint inhibitors in different PD-L1 expression. Methods: We performed a network meta-analysis based on 25 trials involving 12,224 patients with different PD-L1 expression levels. Results: The results showed platinum-based chemotherapy plus pembrolizumab or nivolumab and ipilimumab was associated with the best survival rates for patients with <1% PD-L1 expression, while only platinum-based chemotherapy plus pembrolizumab produced better survival than chemotherapy in patients with 1–49% PD-L1 expression. As for patients with ≥50% PD-L1 expression, platinum-based chemotherapy plus pembrolizumab/atezolizumab and pembrolizumab/cemiplimab monotherapy were associated with better survival than chemotherapy. Conclusion: These results provide reference for selecting the optimum immunotherapy method based on the expression of PD-L1 in patients with advanced lung cancer.

Weight Loss Associated with Platinum-Based Chemotherapy in Patients with Advanced Lung Cancer

Chemotherapy ◽  
2016 ◽  
Vol 61 (5) ◽  
pp. 256-261 ◽  
Author(s):  
Kayoko Morio ◽  
Toshiyuki Minami ◽  
Takashi Sozu ◽  
Kazuyuki Niki ◽  
Takashi Kijima ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Weight Loss ◽  
Cancer Patients ◽  
Therapeutic Effect ◽  
Treatment Completion ◽  
Advanced Lung Cancer ◽  
Completion Rates ◽  
Lung Cancer Patients ◽  
Platinum Based Chemotherapy ◽  
Grade 3

Background: We examined whether the weight loss that occurs with platinum-based chemotherapy in lung cancer patients is associated with chemotherapy side effects, treatment completion rates and therapeutic effect. Methods: We retrospectively reviewed charts of advanced lung cancer patients treated with ≥2 cycles of platinum-based chemotherapy. Patients were divided into 2 groups based on ≥5 or <5% weight loss. Relationships between weight loss and other variables were investigated. Results: Among 114 patients, 18 (15.8%) experienced ≥5% weight loss. Significantly more patients with small-cell lung cancer (SCLC) than with non-SCLC were found to have ≥5% weight loss (30.8 vs. 11.4%, p = 0.023). Patients with ≥5% weight loss experienced higher incidences of grade 3-4 leukopenia (p = 0.008) and neutropenia (p = 0.005), and treatment completion rates were lower in this group (p = 0.035). Weight loss was not significantly associated with therapeutic effect. Conclusion: The weight loss in patients with advanced lung cancer receiving platinum-based chemotherapy is associated with SCLC, grade 3-4 leukopenia, neutropenia and a decrease in treatment completion rate.

TP53 Exon 8 Mutations are Associated with Shorter Survival in Advanced Lung Cancer Patients

2018 ◽  
Author(s):  
Yutao Liu ◽  
Fang Xu ◽  
Yubo Wang ◽  
Qingchen Wu ◽  
Buhai Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document